Alcon Inc. (ALC)
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Alcon: A Re-Rating In Eyesight
Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy
Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
Swiss-American eye care company Alcon on Monday hiked its profit guidance and lowered its estimate for the full-year tariff impact to $40 million to $90 million, factoring in an anticipated refund of around $60 million from the U.S. government.
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alcon (ALC) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Here's Why Alcon (ALC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Do Options Traders Know Something About Alcon Stock We Don't?
Investors need to pay close attention to ALC stock based on the movements in the options market lately.
Alcon (ALC) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
Why Alcon (ALC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
